Abstract
Convection-enhanced delivery (CED) can effectively overcome the blood–brain barrier by infusing drugs directly into diseased sites in the brain using a catheter, but its clinical performance still needs to be improved. This is strongly related to the highly anisotropic characteristics of brain white matter, which results in difficulties in controlling drug transport and distribution in space. In this study, the potential to improve the delivery of six drugs by adjusting the placement of the infusion catheter is examined using a mathematical model and accurate numerical simulations that account simultaneously for the interstitial fluid (ISF) flow and drug transport processes in CED. The results demonstrate the ability of this direct infusion to enhance ISF flow and therefore facilitate drug transport. However, this enhancement is highly anisotropic, subject to the orientation of local axon bundles and is limited within a small region close to the infusion site. Drugs respond in different ways to infusion direction: the results of our simulations show that while some drugs are almost insensitive to infusion direction, this strongly affects other compounds in terms of isotropy of drug distribution from the catheter. These findings can serve as a reference for planning treatments using CED.
Original language | English |
---|---|
Article number | 20240378 |
Number of pages | 13 |
Journal | Journal of the Royal Society Interface |
Volume | 21 |
Issue number | 219 |
DOIs | |
Publication status | Published - 2 Oct 2024 |
Data Availability Statement
Electronic supplementary material is available online at https://doi.org/10.6084/m9.figshare.c.7423804.Funding
This study has received support from the European Union’s H2020 Research and Innovation Programme under grant agreement no. 688279. D.D. also acknowledges the funding received through his Engineering and Physical Sciences Research Council (EPSRC) Established Career Fellowship, EP/N025954/1 and the Shell/RAEng Research Chair in Complex Engineering Interfaces. W.Z. would like to acknowledge the funding received from Children with Cancer UK under the project Children’s Brain Tumour Drug Delivery Consortium grant no. 16-224.
Funders | Funder number |
---|---|
European Research Council | 688279 |
Engineering and Physical Sciences Research Council | EP/N025954/1 |